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Introduction 
With the prevalence of diabetes in the United States increasing and expected to climb higher in 
coming years, eyecare practitioners should have a thorough understanding of the treatment 
and management of diabetic patients. Eyecare providers form part of a team of practitioners, 
that includes primary care medical doctors, endocrinologists, and podiatrists, who should be 
involved in the regular management of diabetic patients. As evidenced by the table below, 
ocular involvement in diabetes is incredibly common and increases with duration. In fact, 
studies have shown that duration of diabetes is the single largest risk factor for development of 
diabetic retinopathy.  
Type Duration Ocular Involvement 
  >10 years 60% have some retinopathy 
1 
>15 years 
Virtually all patients have some degree of retinopathy; 25% 
progress to proliferative DR 
  >20 years 50% progress to proliferative DR 
  At diagnosis 20% have retinopathy 
2  >4 years 4% progress to proliferative DR 
  >15 years 
60%-80% have some retinopathy; up to 20% progress to 
proliferative DR 
 
Table 1. Duration of Diabetes and Risk of Ocular Complications. Adapted from the pamphlet Care of the Patient with 
Diabetes Mellitus, American Optometric Association, 2009. 
 
A detailed understanding of the clinical manifestations, treatment, and pathogenesis of 
diabetes is of importance to the primary eyecare practitioner. This document is designed to 
provide a fundamental and accessible resource for the clinician, with an emphasis on ocular 
signs and diabetic retinopathy.  
Essential pathogenesis of diabetic retinopathy 
Hyperglycemia (elevated blood glucose levels) is at the core of tissue damage resulting from 
diabetes mellitus. Chronically increased blood glucose has been shown to damage blood vessels 
and nerve cells, leading to further complications, including neovascularization, as shown in 
Figure 1. Several biochemical pathways have been identified within this framework. Some of 
the mechanistic pathways thought to play a role in diabetic retinopathy are summarized in 
Figure 2. 
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Figure 1. Chain of Events in Diabetes Leading to Ocular Tissue Damage. Adapted from Fig 6.2, Diabetes and the Eye. (Steele, 
Steel, & Waine, 2008, p. 62). 
 
 
 
 
6 
 
 
Figure 2. Mechanisms of Diabetic Retinopathy. Created by Lee Ann Remington, O.D., M.S. Clinical manifestations of diabetic 
retinopathy 
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                  Figure 3.  Clinical fundus presentation of diabetic retinopathy. Photo by Brandon Reed. 
 
Management of diabetic ocular complications is dependent upon the severity of clinical signs. 
Some of the most common clinical signs of diabetic retinopathy are listed below; relevant 
information pertaining to their genesis and recognition is included. 
 
Cotton Wool Spots (CWS) 
Cotton Wool Spots are so termed due to their fluffy white appearance on fundoscopy.  
 
Why a cotton wool spot is white: “An arrest of the axoplasmic transport will result in an 
accumulation of intracellular organelles that are transported retrogradely from the terminal 
end of the axon in the lateral geniculate body” (Bek, 2010). Swelling of the nerve fiber layer in 
the affected area will cause incoming light to be scattered, accounting for the white appearance 
and indistinct borders.  
 
VF loss with CWS: While small scotomas are possible, they are fairly rare. This is probably due 
to the redundancy of the nerve fiber layer around the affected area. It is even more rare to 
have an arcuate scotoma due to the fact that, “in spite of the disturbance in the axoplasmic 
transport, the conduction of axon potential in the retinal nerve fibers in the affected area has 
remained intact (Bek, 2010). 
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Hard Exudates 
Hard exudates appear as focal, well-defined yellowish-brown flecks or spots during fundoscopy. 
When surrounding the fovea, these spots may resemble a star-like pattern due to orientation of 
the outer plexiform layer fibers in this region. These exudates are composed of precipitated 
serum lipid and protein from surrounding retinal vasculature, and are indicative of a breakdown 
in vessel architecture and increased hydrostatic pressure due to hyperperfusion. Hard exudates 
are predominantly located in the outer plexiform layer of the retina. Discrete hard exudates are 
removed by macrophages in 4-6 months; confluent exudates, however, may take up to a year 
to resolve. Extreme amounts of hard exudates in severe retinopathy may require surgical 
intervention for timely removal. 
 
The Early Treatment of Diabetic Retinopathy Study (ETDRS) showed that an increase in serum 
lipid levels increases the risk of hard exudates in patients with diabetic retinopathy. In 
accordance with this, some case study reports show significant regression of hard exudates 
with lowering of serum lipid levels via medication. 
 
 
Macular Edema 
Macular edema is the single greatest cause of visual impairment in diabetics. It is caused by an 
abnormal accumulation of fluid in retinal tissues because of a disruption in the normal balance 
of hydrostatic, electric and osmotic forces across the vascular wall. The fluid that leaks from 
these vessels enters Müller cells, causing them to swell. Fluid also accumulates in the outer 
plexiform and inner nuclear layers. Other possible causes of damage include liquefaction 
necrosis or hypertrophy of endothelial cells, and pericyte degeneration. 
When Müller cells swell, they sometimes rupture and can cause pockets of fluid in a condition 
known as cystoid macular edema (CME). 
“Several factors are known to cause and influence the development of diabetic macular edema 
due to damage of the retinal vasculature. Leukocytes mediate damage to endothelial cells by 
platelets binding to these cells and inducing the expression of adhesion molecules (P-selectin, 
E-selectin, VCAM-1 and ICAM-1). Furthermore, they increase leukostasis, being one of the first 
histological changes in diabetic retinopathy, occurring prior to any apparent clinical pathology. 
Adherent leukocytes directly induce endothelial cell death in capillaries, causing vascular 
obstruction and vascular leakage. Angiogenic factors, mainly VEGF, cause vascular 
hyperpermeability by leukocyte-mediated endothelial injury. This results in the opening of 
interendothelial junctions and the induction of fenestrations as well as the formation of 
vesiculovacuolar organelles” (Scholl, Kirchhoff, & Augustin, 2010). 
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Microaneurysms 
Microaneurysms are usually less than 100 microns in size and often no larger than 10-25 
microns. “The differentiation of a microaneurysm from a small well defined dot hemorrhage 
cannot be done on the basis of ophthalmoscopy alone, but requires F.A. by which a 
microaneurysm fills with fluorescein, whereas a hemorrhage remains dark” (Bek, 2010). 
A microaneurysm starts with a localized dilation of a retinal capillary, probably secondary to 
increased hydrostatic pressure in the vessel and weakening of the structure of the capillary 
wall. The microaneurysm fills with thrombotic material and hemoglobin as erythrocytes 
become trapped. Vascular walls remain thickened at the site of damage. It is possible that 
microaneurysms may be aborted attempts at neovascularization due to loss of pericytes, which are 
presumed to inhibit endothelial cell proliferation. 
 
Intraretinal Microvascular Abnormalities (IRMA) 
Ophthalmoscopically, IRMA looks like an area of flattened neovascularization and is often found 
near cotton wool spots. Unlike neovascularization however, which looks like a tangled cord, 
IRMA will appear more like a detour around an area of capillary occlusion. During fluorescein 
angiography, an area of IRMA will not leak and it is thought that it serves as a germination bed 
for neovascularization elsewhere (NVE).  
 
Venous Beading 
On fundus examination, venous beading appears as segmentary enlargement or dilation of 
retinal veins, and is often difficult to identify due to its subtlety. Very little is known about the 
exact physiology of venous beading in diabetic retinopathy, although some scientists have 
suggested that it may be an adaptation to increased blood flow. More pronounced venous 
changes may be a result of metabolic acidosis from peripheral ischemia secondary to capillary 
occlusion. 
 
Neovascularization (NVI, NVD, NVE) 
Retinal capillary pericytes most likely play a significant role in inhibiting retinal 
neovascularization. As shown in Figure 2, hyperglycemia can lead to pericyte loss, permitting 
new retinal vessels to arise from venules (rarely from arterioles). This usually occurs at the 
borders of an area of capillary nonperfusion. 
If the neovascular membrane lies flat on the internal surface of neural retina, it is categorized 
as epiretinal. If the area in question is elevated, the membrane is termed preretinal. 
Neovascularization usually begins as epiretinal, but may break through the internal limiting 
membrane (ILM) and be kept in check only by the vitreous. Proteinases associated with 
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endothelial cells may cause local areas of disruption in the ILM and facilitate angiogenesis. With 
time, vitreal shrinkage may cause the new vessels to tear and result in a hemorrhage, thus 
patients with vitreal detachment are at a lower risk for hemorrhage. Vitreal detachments are 
more common in diabetics and tend to occur at an earlier age. “The neovascular growth pattern 
resembles that of fetal angiogenesis where new vessel formation is stimulated by the relative 
ischemia that develops in parallel with the increasing number of metabolically active cells 
during retinal development. The proliferation of endothelial cells from the larger venules forms 
vascular fronts that connect with the arteriolar counterparts to form the microcirculation. 
However, in the mature retina, the newly formed vessels are unable to grow inside the retinal 
tissue to replace occluded vessels. Therefore, the new vessels grow into the vitreous body 
where they may branch extensively and never get to connect with an arteriole to allow 
circulation of the blood” (Bek, 2010). 
Focal retinal depressions 
“Some young patients (<45 years old) exhibit focal depressions in the macular reflex, termed 
the ‘retinal depression sign’. This manifestation results from small retinal depressions that 
reflect light away from the observer so that the macula appears slightly darker than the 
surrounding retina. The feature is best observed by slit-lamp biomicroscopy and is also noted 
on fundus photographs, particularly with red-free filters. This finding may contribute to 
paracentral scotomas and may be confused with epiretinal membranes or macular edema” 
(Scott & Flynn, 2010). 
 
Treatment of diabetic retinopathy 
There are currently many different surgical and pharmacologic treatments for diabetic 
retinopathy. The choice of treatment modality is dependent largely on the severity of the 
retinopathy as well as other systemic considerations. The primary treatment modalities for DR 
are listed below with a brief discussion of the procedure and its use intended for a referring 
eyecare clinician. 
 
Focal laser treatment 
This laser treatment, also known as photocoagulation, can stop or slow the leakage of blood 
and fluid in the eye by using laser burns. It is performed in-office and is usually done in a single 
session. The patient’s vision will be blurry for about a day after the procedure, and they will 
sometimes be aware of small spots in their visual field that are related to the laser treatment. 
These usually disappear within weeks. Blurred vision from swelling of the central macula before 
surgery, however, may prevent recovery of completely normal vision. 
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Scatter laser treatment 
This laser treatment, also known as panretinal photocoagulation, can shrink abnormal blood 
vessels. Also performed in-office, areas of the retina away from the macula are treated with 
scattered laser burns. The burns cause the abnormal new blood vessels to shrink and scar. 
Scatter laser treatment is usually performed in two or more sessions. Blurred vision is common 
for about a day after the procedure. Some loss of peripheral vision or night vision after the 
procedure is possible. 
 
Vitrectomy 
This procedure can be used to remove blood from the middle of the eye (vitreous) as well as 
any scar tissue that's tugging on the retina. It is performed in a surgery center or hospital under 
local or general anesthesia. During the procedure, the doctor makes a tiny incision in order to 
remove scar tissue and blood in the eye with delicate instruments, and replace it with a salt 
solution. The salt solution helps maintain the eye's normal shape. Sometimes a gas bubble must 
be placed in the cavity of the eye to help reattach the retina. If a gas bubble was placed in the 
eye, the patient may need to remain in a facedown position until the gas bubble dissipates — 
often several days. The patient will be required to wear an eye patch and use medicated 
eyedrops for a few days or weeks. Vitrectomy may be followed or accompanied by laser 
treatment. 
 
 
Management of diabetic patients 
The management of diabetic patients is dependent upon the severity of the disease, as well as 
additional factors such as the presence of clinically significant macular edema (CSME) and 
systemic health risks. Each case should be considered individually, and a more cautious 
approach to treatment, with input from specialists if necessary, is generally recommended. 
Several studies, most notably the ETDRS, have been instrumental in helping to define standards 
for the grading of diabetic retinopathy. These standards are listed in the table below, and the 
corresponding standard photos may be viewed in stereo at the website for the University of 
Wisconsin-Madison’s Fundus Photograph Reading Center.  Table 2 is a reference of clinical 
findings in diabetic retinopathy by level of severity of the disease.  
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Severity of Diabetic Retinopathy  Clinical Findings 
Mild Non-proliferative Diabetic Retinopathy 
(NPDR) 
Microaneurysms only 
Moderate NPDR More severe than mild NPDR, but less than severe 
NPDR 
Severe NPDR Any one of the following without PDR: 
 >20 intraretinal hemorrhages in all four 
quadrants 
 Venous beading in 2 quadrants 
 IRMA in one quadrant 
Proliferative diabetic retinopathy (PDR) One or more of the following: 
 Any neovascularization of the iris (NVI), 
disc (NVD), angle (NVA), or elsewhere 
(NVE) 
 Vitreous/preretinal hemorrhage 
High-Risk PDR^ PDR with any one of the following: 
 NVD greater than 1/4 to 1/3 of disc area 
in size 
 Any NVD associated with preretinal or 
vitreous hemorrhage 
 NVE > ½ of disc area and associated with 
preretinal or vitreous hemorrhage 
 Any NVI 
 Any neovascularization of the angle 
Diabetic macular edema (DME)* Macular edema not qualifying as CSME 
Clinically significant macular edema (CSME)* Any one of the following: 
 Retinal thickening within 500um (~1/3 
disc diameter) of center of fovea 
 Hard exudates within 500um of center of 
fovea and adjacent to an area of retinal 
thickening 
 Retinal thickening over one disc area in 
size, any part of which is within one disc 
diameter of foveal center 
^High-risk PDR requires treatment by panretinal photocoagulation 
*DME and CSME may be present in any stage of diabetic retinopathy 
Table 2. Clinical Findings in Diabetic Retinopathy. 
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A number of guidelines have been published to direct eyecare practitioners in appropriate 
management of diabetic retinopathy. The following table is adapted from information in the 
American Academy of Ophthalmology’s Preferred Practice Pattern document on Diabetic 
Retinopathy. We encourage downloading the original document, free to practitioners, which 
clarifies the information found below, here.  
 
Severity of Diabetic Retinopathy 
Recommended 
Follow-up PRP FA Focal/Grid Laser 
Normal or Trace NPDR - No CSME 12 mo No No No 
Mild-moderate NPDR -  No CSME 6-12 mo No No No 
Mild-moderate NPDR -  CSME 2-4 mo No Usually Usually 
Severe NPDR -          No CSME 2-4 mo Sometimes Rarely No 
Severe NPDR -          CSME 2-4 mo Sometimes Usually Usually 
Non-high risk PDR -     No CSME 2-4 mo Sometimes Rarely No 
Non-high risk PDR -     CSME 2-4 mo Sometimes Usually Usually 
High-risk PDR -         No CSME 2-4 mo Usually Rarely No 
High-risk PDR -         CSME 2-4 mo Usually Usually Usually 
 
Table 3. Management of Diabetic Retinopathy. 
 
For the referring eyecare clinician, it is generally recommended that a patient with diabetic 
retinopathy be sent for a consultation with a diabetes specialist (i.e. retinal surgeon) based on 
the following timeframe by clinical signs: 
 Refer within 2-4 weeks if: macular edema, early PDR, very severe NPDR 
 Refer within 24 hours if: high risk PDR or vitreous hemorrhage 
In addition to managing the ocular aspects of diabetes, eyecare practitioners should be keenly 
aware of the general systemic guidelines for diabetes management. Encouraging diabetic 
patients to actively monitor their blood glucose and blood pressure levels reinforces for these 
patients the importance of maintaining their health and avoiding advanced complications of the 
disease. Published guidelines for systemic control of diabetes are listed in the table below. 
Individual patients may have differing guidelines based upon their primary care practitioner’s or 
endocrinologist’s recommendations. 
 
 
 
 
14 
 
                   
Glycemic control  
  
A1C < 7.0% 
Preprandial plasma 
glucose (before a meal) 
70–130 mg/dl (5.0–7.2 
mmol/l) 
Postprandial plasma 
glucose (after a meal) 
< 180 mg/dl (<10.0 
mmol/l) 
Blood pressure < 130/80 mmHg 
Lipids    
LDL < 100 mg/dl (<2.6 
mmol/l) 
Triglycerides < 150 mg/dl (<1.7 
mmol/l) 
HDL > 40 mg/dl (>1.1 mmol/l) 
 
Table 4. Recommended Values for systemic markers of diabetic health. Adapted from the American Diabetic Association.  
 
A reference for common diabetes medications 
It is valuable for practitioners managing diabetic patients in any capacity to recognize and have 
basic familiarity with common medications used in treating diabetes. General information 
regarding some of the more common diabetic insulins are listed below: 
Insulins (not exhaustive):  
 Lispro – extremely fast-acting 
 Aspartate – extremely fast-acting 
 Glulisine – extremely fast-acting 
 Lantus – long duration allows for 24-hr control 
 Levimir – long duration allows for 24-hr control 
 Humulin – intermediate-acting 
 Iletin – intermediate-acting 
 Novolin – intermediate-acting 
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Note that insulin may be delivered in any of the following methods: 
 Syringe (subcutaneous) 
 Insulin Pens 
 Continuous Subcutaneous Insulin Infusion (for highly committed, responsible patients) 
 Inhalation 
Oral medications are the first line of treatment for type 2 diabetics. The following table lists the 
major classes of oral medications for diabetes, along with the most common drugs within each 
class and their mechanism of action. 
 
 
Drug Class Medications Action 
Thiazolidinedione (TZD) Rosiglitazone (Actos) Improves action of insulin in liver 
and skeletal muscles Pioglitazone (Avandia) 
Biguanide (first-line therapy) Metformin (Glucophage/XL) Decreases liver gluconeogenesis 
and increases glucose uptake by 
skeletal muscle 
Sulfonylurea Glimiperide (Amaryl) Stimulate release of insulin from 
beta cells in the pancreas Glyburide (Macronase, DiaBeta) 
Glipizide (Glucotrol/XL, Glynase)  
Alpha-Glucosidase Inhibitor Acarbose (Precose) Slows carbohydrate breakdown, 
decreases glucose absorption Miglitol (Glyset)  
DPP4 Inhibitor Sitagliptin Slows incretin inactivation, 
which increases insulin secretion 
and decreases glucagon release 
Meglitinide Repaglinide (Prandin) Short-acting; stimulates insulin 
secretion Nateglinide (Starlix) 
 
Table 5. Overview of Oral Medications in Diabetes. 
In addition to the above medications, a number of newer combination medications including 
two or more of the above are available. 
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Summary 
With the current prevalence of diabetes and its anticipated increase in the future, primary 
eyecare practitioners are placed at the forefront of detection and management of a major 
public health concern. It is imperative that primary eye clinicians are skilled in understanding 
the complex pathology, diagnosis, and treatment course of diabetes and its effects on the eye 
as well as throughout the body. Further exploration of the topics covered in this manual is 
encouraged, and the list of references that follows is recommended. It is the authors’ hope that 
readers of this manual will be motivated to offer the best of care to diabetic patients by 
keeping appraised of updates and advances in the medical sciences as they develop, and 
particularly as pertaining to the primary eyecare clinician’s role in the management of diabetes.  
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